Pacira reported 80.9 in PE Price to Earnings for its fiscal quarter ending in September of 2026.





Pe Change Date
Astellas Pharma 9.57 0.16 Sep/2026
Bristol-Myers Squibb 10.44 5.7 Sep/2026
Cara Therapeutics 0.49 27.28 Mar/2026
Ironwood Pharmaceuticals 204.24 88.19 Dec/2024
J&J 25.86 3.57 Sep/2026
Ligand Pharmaceuticals 68.1 16.21 Sep/2026
Novo Nordisk 10.17 2.61 Jun/2026
Pacira 80.9 45.22 Sep/2026
Perrigo 21.11 6.34 Sep/2026
Pfizer 15.2 3.72 Sep/2026
Supernus Pharmaceuticals 72.26 6.89 Sep/2026
Teva Pharmaceutical Industries 18.7 5.9 Sep/2026
Xeris Pharmaceuticals 92.28 16.23 Jun/2026
Zoetis 11.38 0.8 Sep/2026